Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas

Michele Merli; Dario Marino; Emanuele Cencini; Sara Rattotti; Costanza Fraenza; Paolo Grossi; Benedetta Bianchi; Barbara Mora; Roberta Sciarra; Silvia Finotto; Bianca Mecacci; Francesco Passamonti; Carlo Visco; Luca Arcaini

doi:10.1002/hon.2825

Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas

Michele Merli, Dario Marino, Emanuele Cencini, Sara Rattotti, Costanza Fraenza, Paolo Grossi, Benedetta Bianchi, Barbara Mora, Roberta Sciarra, Silvia Finotto, Bianca Mecacci, Francesco Passamonti, Carlo Visco, Luca Arcaini

Research output: Contribution to journal › Letter › peer-review

Original language	English
Number of pages	4
Journal	Hematological Oncology
DOIs	https://doi.org/10.1002/hon.2825
Publication status	E-pub ahead of print - Nov 5 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1002/hon.2825

Cite this

Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas. / Merli, Michele; Marino, Dario; Cencini, Emanuele; Rattotti, Sara; Fraenza, Costanza; Grossi, Paolo; Bianchi, Benedetta; Mora, Barbara; Sciarra, Roberta ; Finotto, Silvia; Mecacci, Bianca; Passamonti, Francesco; Visco, Carlo; Arcaini, Luca.

In: Hematological Oncology, 05.11.2020.

Research output: Contribution to journal › Letter › peer-review

Merli, Michele ; Marino, Dario ; Cencini, Emanuele ; Rattotti, Sara ; Fraenza, Costanza ; Grossi, Paolo ; Bianchi, Benedetta ; Mora, Barbara ; Sciarra, Roberta ; Finotto, Silvia ; Mecacci, Bianca ; Passamonti, Francesco ; Visco, Carlo ; Arcaini, Luca. / Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas. In: Hematological Oncology. 2020.

@article{39069700b1174e729af649a253be2163,

title = "Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas",

author = "Michele Merli and Dario Marino and Emanuele Cencini and Sara Rattotti and Costanza Fraenza and Paolo Grossi and Benedetta Bianchi and Barbara Mora and Roberta Sciarra and Silvia Finotto and Bianca Mecacci and Francesco Passamonti and Carlo Visco and Luca Arcaini",

note = "Funding Information: The Varese group was supported by grants of the Fondazione Regionale Ricerca Biomedica (FRRB), Milan, Italy (FRRB project no. 2015‐0042, genomic profiling of rare hematologic malignancies, development of personalized medicine strategies, and their implementation into the Rete Ematologica Lombarda clinical network), by Fondazione Matarelli (Milano, Italy) and AIL Varese ONLUS. Funding Information: Paolo Grossi has been paid scientific advisor for MSD, Biotest, Angelini, Nordic Pharma and received lecture fees from Vertex. Francesco Passamonti has been paid scientific advisor for Roche, Novartis, Gilead Sciences and received lecture fees from Novartis, Gilead Sciences. Luca Arcaini has been paid scientific advisor for Roche, Bayer, Celgene, Sandoz, Verastem and Gilead Sciences, received research funding from Gilead Sciences, received personal fees from Roche, Celgene, Gilead Sciences, EUSA Pharma and received lecture fees from Celgene. The other authors declare no potential conflict of interest. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = nov,

day = "5",

doi = "10.1002/hon.2825",

language = "English",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "wiley",

}

TY - JOUR

T1 - Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas

AU - Merli, Michele

AU - Marino, Dario

AU - Cencini, Emanuele

AU - Rattotti, Sara

AU - Fraenza, Costanza

AU - Grossi, Paolo

AU - Bianchi, Benedetta

AU - Mora, Barbara

AU - Sciarra, Roberta

AU - Finotto, Silvia

AU - Mecacci, Bianca

AU - Passamonti, Francesco

AU - Visco, Carlo

AU - Arcaini, Luca

N1 - Funding Information: The Varese group was supported by grants of the Fondazione Regionale Ricerca Biomedica (FRRB), Milan, Italy (FRRB project no. 2015‐0042, genomic profiling of rare hematologic malignancies, development of personalized medicine strategies, and their implementation into the Rete Ematologica Lombarda clinical network), by Fondazione Matarelli (Milano, Italy) and AIL Varese ONLUS. Funding Information: Paolo Grossi has been paid scientific advisor for MSD, Biotest, Angelini, Nordic Pharma and received lecture fees from Vertex. Francesco Passamonti has been paid scientific advisor for Roche, Novartis, Gilead Sciences and received lecture fees from Novartis, Gilead Sciences. Luca Arcaini has been paid scientific advisor for Roche, Bayer, Celgene, Sandoz, Verastem and Gilead Sciences, received research funding from Gilead Sciences, received personal fees from Roche, Celgene, Gilead Sciences, EUSA Pharma and received lecture fees from Celgene. The other authors declare no potential conflict of interest. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/11/5

Y1 - 2020/11/5

UR - http://www.scopus.com/inward/record.url?scp=85096687482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096687482&partnerID=8YFLogxK

U2 - 10.1002/hon.2825

DO - 10.1002/hon.2825

M3 - Letter

C2 - 33150988

AN - SCOPUS:85096687482

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

ER -